stockrowZai Lab Limited Unsponsored ADR
ZLAB Healthcare Biotechnology
Zai Lab Limited Unsponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $460.2 million, up 15.3% from fiscal 2024.
- Revenue
- −6.79%
- EPS
- −24.3%
- Free cash flow
- −95.5%
- Total debt
- +24.3%
Quarter to September 2026, against a year earlier
Follow ZLAB
Alert me
Zai Lab Limited Unsponsored ADR (ZLAB) EPS (diluted)
Zai Lab Limited Unsponsored ADR's EPS (diluted) for fiscal 2025 was −$1.60, compared with −$2.60 in fiscal 2024. Over the twelve months to 30 June 2026 it was −$1.71. Over the past ten years it has ranged from −$7.58 (fiscal 2021) to −$1.60 (fiscal 2025) — the current reading is the highest in ten years. EPS (diluted) has risen for 4 consecutive fiscal years. Zai Lab Limited Unsponsored ADR ranks 296th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$1.60 | — |
| FY2024 | −$2.60 | — |
| FY2023 | −$3.50 | — |
| FY2022 | −$4.63 | — |
| FY2021 | −$7.58 | — |
| FY2020 | −$3.46 | — |
| FY2019 | −$3.03 | — |
| FY2018 | −$2.64 | — |
| FY2017 | −$2.32 | — |
| FY2016 | −$3.97 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | −$0.46 | — |
| Mar 2026 | −$0.46 | — |
| Dec 2025 | −$0.46 | — |
| Sep 2025 | −$0.33 | — |
| 27 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| ADMA ADMA Biologics Inc compare | $0.77 |
| RXRX Recursion Pharmaceuticals, Inc. compare | −$0.90 |
| NAMS NewAmsterdam Pharma Company N.V. compare | −$1.69 |
| ZLAB Zai Lab Limited Unsponsored ADR | −$1.71 |
| XNCR Xencor, Inc. compare | −$2.17 |
| MBX MBX Biosciences, Inc. compare | −$2.41 |
| PHVS Pharvaris N.V. compare | −$3.05 |
| RCUS Arcus Biosciences, Inc. compare | −$3.63 |
| CLDX Celldex Therapeutics, Inc. compare | −$4.35 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on ZLAB
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement